Citation: Heping Hu, Lijia Yu, Zhao Ding, Jinsong Ding, Yiguo Hu, Zongning Yin. Chemo–immunotherapy for chemo-resistance and metastasis of triple-negative breast cancer by combination of iron-oxide nanoparticles and dual-targeting doxorubicin liposomes[J]. Chinese Chemical Letters, ;2023, 34(10): 108592. doi: 10.1016/j.cclet.2023.108592 shu

Chemo–immunotherapy for chemo-resistance and metastasis of triple-negative breast cancer by combination of iron-oxide nanoparticles and dual-targeting doxorubicin liposomes

Heping Hu ^a ,
Lijia Yu ^b ,
Zhao Ding ^c ,
Jinsong Ding ^d ,
Yiguo Hu ^e ,
Zongning Yin ^{a, *,}

a.
Key Laboratory of Drug Targeting and Drug Delivery System of Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu 610041, China
b.
Sichuan Huiyu Seacross Medical Technology Co., Ltd., Chengdu 610031, China
c.
Sichuan Huiyu Pharmaceutical Co., Ltd., Neijiang 641000, China
d.
Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410013, China
e.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610044, China

yzn@scu.edu.cn

Received Date: 5 February 2023
Revised Date: 13 May 2023
Accepted Date: 18 May 2023
Available Online: 19 May 2023

Figures(4)

Triple-negative breast cancer (TNBC) lacks specific regimens for targeted therapy. Repeat chemotherapy promotes the evolution of TNBC into highly chemo-resistant tumors that metastasize to multiple organs simultaneously. Herein, polyacrylic acid-coated ultrasmall superparamagnetic iron-oxide nanoparticles (PAA@IONs) and dual-targeting doxorubicin liposomes achieved chemo–immunotherapy through intermittent administration. They inhibited tumor-drug resistance and multiorgan-specific metastasis significantly by targeting tumors and the microenvironment. We deciphered an immunosuppressive pre-metastatic niche and discovered that PAA@IONs could target tumors, tumor-draining lymph nodes (TDLNs), the liver, bone, and lungs. They promoted the polarization of macrophages into M1 macrophages in these organs and tissues. This action remodeled the immunosuppressive microenvironment and induced a sustained immune response, thereby reducing organ-specific metastasis. Overcoming the disadvantages of doxorubicin-induced cardiotoxicity as well as low tumor specificity, dual peptide-modified liposomes could target CD206 and CD13 simultaneously, and reverse chemo-resistance. These properties resulted in a significant decrease in the numbers of myeloid-derived suppressor cells (MDSCs) and cancer stem cells (CSCs) in the liver, lungs, and bone, thereby reducing protein expression of Ki-67 in TDLNs, and dramatically increasing the number of cluster of differentiation (CD)8⁺T cells and CD8⁺ T cell/T-regulatory-cell ratio in tumors and TDLNs (P < 0.0001). Compared with the control (P < 0.05 and P < 0.01, respectively) or free drug (P < 0.0001 and P < 0.01, respectively), multi-organ metastases were suppressed significantly, tumor-growth rate reduced, and survival prolonged. Our drug-delivery system overcame TNBC chemo-resistance and inhibited multiorgan-specific metastases. It circumvents the lack of effective therapeutic targets, the problem of patient selection due to a low mutation rate, and can simultaneously offer the possibility of avoiding surgery and considerable postoperative complications.
- Multidrug resistance,
- Multiorgan-specific metastases,
- Immunogenic cell death,
- Intermittent dosing,
- Immunosuppressive tumor microenvironment,
- Tumor-associated macrophages
1. [1]
  L. Vecchi, S.T.S. Mota, M.A.P. Zoia, et al., Cells 11 (2022) 1705. doi: 10.3390/cells11101705
2. [2]
  X. Qiu, Y. Qu, B. Guo, et al., J. Control. Release. 341 (2022) 498–510. doi: 10.1016/j.jconrel.2021.12.002
3. [3]
  L. Biganzoli, N.M.L. Battisti, H. Wildiers, et al., Lancet Oncol. 22 (2021) e327–e340. doi: 10.1016/S1470-2045(20)30741-5
4. [4]
  D. Zhang, F. Feng, R. Liu, W. Zhu, L. Yao, Chin. Chem. Lett. 30 (2019) 7–14. doi: 10.1016/j.cclet.2018.06.011
5. [5]
  I. Fatima, I. El-Ayachi, H.C. Playa, et al., Cancers 11 (2019) 2039. doi: 10.3390/cancers11122039
6. [6]
  H. du Bois, T.A. Heim, A.W. Lund, Sci. Immunol. 6 (2021) eabg3551. doi: 10.1126/sciimmunol.abg3551
7. [7]
  Y.Y. Chen, J.Y. Ge, D. Ma, K.D. Yu, Front. Oncol. 10 (2020) 570981. doi: 10.3389/fonc.2020.570981
8. [8]
  D.I. Tsilimigras, P. Brodt, P.A. Clavien, et al., Nat. Rev. Dis. Primers 7 (2021) 27. doi: 10.1038/s41572-021-00261-6
9. [9]
  A.G. Waks, E.P. Winer, JAMA. 321 (2019) 288–300. doi: 10.1001/jama.2018.19323
10. [10]
  E. Avitabile, D. Bedognetti, G. Ciofani, A. Bianco, L.G. Delogu, Nanoscale 10 (2018) 11719–11731. doi: 10.1039/C8NR02796J
11. [11]
  V. Tripathi, J.H. Shin, C.H. Stuelten, Y.E. Zhang, Oncogene, 38 (2019) 3185–3200. doi: 10.1038/s41388-018-0655-8
12. [12]
  F. Emami, S. Pathak, T.T. Nguyen, et al., J. Control. Release. 329 (2021) 645–664. doi: 10.1016/j.jconrel.2020.10.001
13. [13]
  K. Irshad, C. Srivastava, N. Malik, et al., Front. Immunol. 13 (2022) 813888. doi: 10.3389/fimmu.2022.813888
14. [14]
  Y. Wang, J. Yu, Z. Luo, et al., Adv. Mater. 33 (2021) e2103497. doi: 10.1002/adma.202103497
15. [15]
  Y. Jiang, Y. Li, B. Zhu, Cell Death Dis. 6 (2015) e1792. doi: 10.1038/cddis.2015.162
16. [16]
  S. Zhu, N. Yang, J. Wu, Pharmacol. Res. 159 (2020) 104980. doi: 10.1016/j.phrs.2020.104980
17. [17]
  S. Zanganeh, G. Hutter, R. Spitler, et al., Nat. Nanotechnol. 11 (2016) 986–994. doi: 10.1038/nnano.2016.168
18. [18]
  R. Zhang, F. Qi, F. Zhao, et al., Cell Death Dis. 10 (2019) 273. doi: 10.1109/iecon.2019.8927061
19. [19]
  Z. Chen, J. Wu, L. Wang, H. Zhao, J. He, Med. Oncol. 39 (2022) 83. doi: 10.1007/s12032-022-01670-7
20. [20]
  L. Fu, X. Ma, Y. Liu, Z. Xu, Z. Sun, Chin. Chem. Lett. 33 (2022) 1718–1728. doi: 10.1016/j.cclet.2021.10.074
21. [21]
  J. Wang, D. Li, H. Cang, B. Guo, Cancer Med. 8 (2019) 4709–4721. doi: 10.1002/cam4.2327
22. [22]
  J. Chen, X. Yu, X. Liu, et al., Nanoscale 14 (2022) 12984–12998. doi: 10.1039/d2nr04418h
23. [23]
  L. Liu, F. Zeng, Y. Li, et al., Nanoscale 14 (2022) 4073–4081. doi: 10.1039/d1nr07449k
24. [24]
  S. Niu, G.R. Williams, J. Wu, et al., Chem. Eng. J. 369 (2019) 134–149. doi: 10.1016/j.cej.2019.02.201
25. [25]
  M. Louca, V. Gkretsi, Cancers 14 (2022) 4528. doi: 10.3390/cancers14184528
26. [26]
  M.F. Fransen, M. Schoonderwoerd, P. Knopf, et al., JCI Insight 3 (2018) e124507. doi: 10.1172/jci.insight.124507
27. [27]
  X. Zhu, L. Chen, B. Huang, et al., Sci. Rep. 10 (2020) 225. doi: 10.1038/s41598-019-57094-3
28. [28]
  Y. Chu, T. Sun, C. Jiang, Chin. Chem. Lett. 33 (2022) 4157–4168. doi: 10.1016/j.cclet.2022.02.051
29. [29]
  L. Yang, P. Shi, G. Zhao, J. Xu, et al., Signal Transduct. Target. Ther. 5 (2020) 8. doi: 10.1089/acm.2019.0105
30. [30]
  K. Hu, H. Zhou, Y. Liu, et al., Nanoscale 7 (2015) 8607–8618. doi: 10.1039/C5NR01084E
1. [1]
  Yunyan Li , Zimin Cai , Zhicheng Wang , Sifeng Zhu , Wendian Liu , Cheng Wang . Construction of biomimetic hybrid nanovesicles based on M1 macrophage-derived exosomes for therapy of cancer. Chinese Chemical Letters, 2025, 36(4): 109942-. doi: 10.1016/j.cclet.2024.109942
2. [2]
  Xueying Shi , Xiaoxuan Zhou , Bing Xiao , Hongxia Xu , Wei Zhang , Hongjie Hu , Shiqun Shao , Zhuxian Zhou , Youqing Shen , Xiaodan Xu , Jianbin Tang . A β-lapachone-loaded iron-polyphenol nanocomplex enhances chemodynamic therapy through cascade amplification of ROS in tumor. Chinese Chemical Letters, 2025, 36(5): 110178-. doi: 10.1016/j.cclet.2024.110178
3. [3]
  Kun-Heng Li , Hong-Yang Zhao , Dan-Dan Wang , Ming-Hui Qi , Zi-Jian Xu , Jia-Mi Li , Zhi-Li Zhang , Shi-Wen Huang . Mitochondria-targeted nano-AIEgens as a powerful inducer for evoking immunogenic cell death. Chinese Chemical Letters, 2024, 35(5): 108882-. doi: 10.1016/j.cclet.2023.108882
4. [4]
  Yanjun Cai , Yong Jiang , Yu Chen , Erzhuo Cheng , Yuan Gu , Yuwei Li , Qianqian Liu , Jian Zhang , Jifang Liu , Shisong Han , Bin Yang . Amplifying STING activation and immunogenic cell death by metal-polyphenol coordinated nanomedicines for enhanced cancer immunotherapy. Chinese Chemical Letters, 2025, 36(5): 110437-. doi: 10.1016/j.cclet.2024.110437
5. [5]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
6. [6]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
7. [7]
  Honghao Sun , Huimin Zhao , Ronghui Yin , Chenxi Zhou , Ming Wu , Yueyang Deng , Zhanwei Zhou , Minjie Sun . Injectable hydrogel-based tumor vaccine with fibrotic tumor immune microenvironment remodeling to prevent breast cancer postoperative recurrence and metastases. Chinese Chemical Letters, 2025, 36(5): 110067-. doi: 10.1016/j.cclet.2024.110067
8. [8]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
9. [9]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
10. [10]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
11. [11]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
12. [12]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
13. [13]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
14. [14]
  Jiahao Liu , Peng Liu , Junhong Duan , Qiongxuan Xie , Jie Feng , Hongpei Tan , Ze Mi , Ying Li , Yunjie Liao , Pengfei Rong , Wenhu Zhou , Xiang Gao . Macrophages-mediated tumor accumulation and deep penetration of bismuth/manganese biomineralized nanoparticles for enhanced radiotherapy. Chinese Chemical Letters, 2024, 35(12): 109632-. doi: 10.1016/j.cclet.2024.109632
15. [15]
  Xiaohong Wen , Mei Yang , Lie Li , Mingmin Huang , Wei Cui , Suping Li , Haiyan Chen , Chen Li , Qiuping Guo . Enzymatically controlled DNA tetrahedron nanoprobes for specific imaging of ATP in tumor. Chinese Chemical Letters, 2024, 35(8): 109291-. doi: 10.1016/j.cclet.2023.109291
16. [16]
  Ying Gao , Rong Zhou , Qiwen Wang , Shaolong Qi , Yuanyuan Lv , Shuang Liu , Jie Shen , Guocan Yu . Natural killer cell membrane doped supramolecular nanoplatform with immuno-modulatory functions for immuno-enhanced tumor phototherapy. Chinese Chemical Letters, 2024, 35(10): 109521-. doi: 10.1016/j.cclet.2024.109521
17. [17]
  Yuanzheng Wang , Chen Zhang , Shuyan Han , Xiaoli Kong , Changyun Quan , Jun Wu , Wei Zhang . Cancer cell membrane camouflaged biomimetic gelatin-based nanogel for tumor inhibition. Chinese Chemical Letters, 2024, 35(11): 109578-. doi: 10.1016/j.cclet.2024.109578
18. [18]
  Qianyun Ye , Yuanyuan Liang , Yuhe Yuan , Xiaohuan Sun , Liqi Zhu , Xuan Wu , Jie Han , Rong Guo . pH-responsive chiral supramolecular cysteine-Zn²⁺-indocyanine green assemblies for triple-level chirality-specific anti-tumor efficacy. Chinese Chemical Letters, 2025, 36(5): 110432-. doi: 10.1016/j.cclet.2024.110432
19. [19]
  Yang Liu , Minglu Li , Jianxun Ding , Xuesi Chen . Glycoengineering-assistant biomineralization for tumor blockade therapy. Chinese Chemical Letters, 2025, 36(5): 110146-. doi: 10.1016/j.cclet.2024.110146
20. [20]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840

Get Citation

PDF

XML

Metrics

PDF Downloads(5)
Abstract views(509)
HTML views(33)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142